...
首页> 外文期刊>Biopharmaceutics and Drug Disposition >Pharmacokinetics of Intravenous Methotrexate in Mutant Nagase Analbuminemic Rats
【24h】

Pharmacokinetics of Intravenous Methotrexate in Mutant Nagase Analbuminemic Rats

机译:静脉注射甲氨蝶呤在突变的Nagase贫血大鼠中的药代动力学

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

It has been reported that the plasma (or serum) levels of albumin and globulins were lower and higher, respectively, than the serum levels in control rats. Hence, it could be expected that these changes could affect the renal clearance (Cl_r) of methotrexate in Nagase analbuminemic rats (NARs) due to changes in plasma protein binding values. Therefore, methotrexate at a dose of 100mg/kg was administered intravenously to control rats and NARs. The plasma protein binding of methotrexate in NARs was significantly greater (29.4% increase) than the controls, probably due to the considerable binding of the drug (34.2%) to 1.8% beta-plus 0.63% gamma-globulins. The Cl_r of methotrexate in NARs was significantly slower (36.1% decrease) than the controls, due to the significantly smaller Ae_(o-24h) (25.8% decrease). The smaller Ae_(o_24h) could be due to the significantly smaller free (unbound to plasma proteins) fractions of methotrexate in plasma (13.8% decrease) in NARs, since methotrexate was mainly excreted in the urine via glomerular filtration. However, the Cl_(nr) values were comparable between the control rats and NARs. This could be because methotrexate is not metabolized considerably via hepatic CYP isozymes based on control rats pretreated with SKF 525-A (a nonspecific inhibitor of hepatic CYP isozymes in rats). Copyright ? 2007 John Wiley & Sons, Ltd.
机译:据报道,白蛋白和球蛋白的血浆(或血清)水平分别低于对照组大鼠的血清水平。因此,可以预料,由于血浆蛋白结合值的变化,这些变化可能会影响长濑脱氨性大鼠(NAR)中甲氨蝶呤的肾脏清除率(Cl_r)。因此,以100mg / kg的剂量甲氨蝶呤静脉内给药以控制大鼠和NAR。 NAR中甲氨蝶呤的血浆蛋白结合率明显高于对照组(增加29.4%),这可能是由于该药物与1.8%β-加0.63%γ-球蛋白的显着结合(34.2%)所致。 NARs中甲氨蝶呤的Cl_r明显慢于对照(降低36.1%),这是由于Ae_(o-24h)显着较小(降低了25.8%)。较小的Ae_(o_24h)可能是由于NAR中血浆中甲氨蝶呤的游离(未结合血浆蛋白)部分明显较少(下降13.8%),因​​为甲氨蝶呤主要通过肾小球滤过排泄在尿液中。但是,Cl_(nr)值在对照组和NAR之间是可比的。这可能是因为基于以SKF 525-A(大鼠肝CYP同工酶的非特异性抑制剂)预处理的对照大鼠,甲氨蝶呤不会通过肝CYP同工酶大量代谢。版权? 2007年John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号